Lisata Therapeutics, Inc.

Welcome to the La Sada Therapeutics fourth quarter and full year 2022 financial results and business update conference call. Currently, all participants are in listen-only mode. Following management's prepared remarks, we will hold a Q&A session. To ask a question at that time, please press star 11 on your telephone. You will then hear an automated message advising you that your hand is raised. As a reminder, this call is being recorded today, Thursday, March 30th, 2023. I will now turn the call over to John Mendito, Vice President of Investor Relations and Corporate Communications at La Sada. Please go ahead, sir.

Thank you, operator, and good afternoon, everyone. Welcome to OSADA's fourth quarter and full year 2022 conference call to discuss our financial results and provide a business update. Joining me today from our management team are Dr. David Mazzo, Chief Executive Officer, Dr. Kristen Buck, Executive Vice President of Research and Development and Chief Medical Officer, and James Nisko, Vice President of Finance and Treasuries. Shortly before this call, we issued a press release announcing our fourth quarter and full year 2022 financial results, which is available under the Investors and News section of the company website, along with the webcast replay of this call. If you have not received this news release or you would like to be added to the company's email distribution list, please email me at jmendito at lazada.com. Before we begin, I will remind you that comments made by management during this conference call will contain forward-looking statements that involve risks and uncertainties regarding the operations and future results of LASADA. I encourage you to review the company's filings with the Securities and Exchange Commission, including without limitation its forms 10Q, 8K, and 10K, which identify specific risk factors that may cause actual results or events to differ materially from those described in the forward-looking statements. Furthermore, the content of this conference call contains time-sensitive information that is accurate only as of the date of live broadcast, March, sorry, Thursday, March 30th, 2023. Nezada Therapeutics undertakes no obligation to revise or update any statements to reflect events or circumstances after the date of this conference call. With that, I will now turn the call over to Dr. Mazza. Dave?

Thank you, John, and good afternoon, everyone. Thank you for once again joining us as we provide an overview of recent business highlights and discuss our fourth quarter and full year 2022 financial results. 2022 was a year of exciting transformation for the company, leading to the emergence of Lasada Therapeutics, a financially stable clinical stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases. Our portfolio of product candidates contains treatments in development that are designed to be regenerative and or to bring significant therapeutic improvement. ListaOne, our lead investigational product candidate from the Sendar platform, is the subject of multiple planned and ongoing clinical trials being conducted globally in a variety of solid tumor types and in combination with several anti-cancer agents. Based on substantial preclinical and importantly early human clinical data, we believe that ListaOne has the potential to become an integral part of a revised standard of care therapy for many difficult to treat cancers. Our chief medical officer, Dr. Kristen Buck, will provide more specifics on our clinical programs shortly following our review of the financial results. However, before we get into that and our financial review, I do want to emphasize some of the characteristics of our company that the general market has overlooked. Those who follow the biotech biopharma space will undoubtedly know that there are between 200 and 250 companies at any given time today with a market capitalization below their cash balance. We are, in fact, one of those companies. However, unlike most of those companies that are without sufficient cash to execute their development plans through key milestones and are facing extremely difficult and costly financings this year, if they can finance at all, we are well financed through critical milestones on our key programs. In fact, we are able to project available cash lesting well into the middle of 2025. That's more than two years of operational funding covering almost one dozen clinical programs, the vast majority of which are designed as blinded, controlled, randomized studies. This is the type of study that yields the most definitive data regarding a development candidate's safety and efficacy. It is our firm belief that as more and more companies succumb to financial pressures, and pair their programs, resort to smaller and less definitive study designs, and or fold completely, the market will recognize the strength of our financial position and the robustness of our development strategy. To use an often used analogy, we have many shots on goal, any one of which could provide significant value creation over the next two years. With that in mind, our internal focus is on rapid, efficient, and cost-effective execution and continued rigorous capital management. all leading to what we anticipate will be positive study data and benefits for patients, physicians, and our shareholders. And with that, I now will turn the call over to James Nisko, our Vice President of Finance and Treasury, to review and provide commentary on our fourth quarter and full year 2022 financial results. James?